Key Takeaway: Pfizer announced positive topline results from its Phase 3 MagnetisMM-32 study of ELREXFIO in relapsed or refractory multiple myeloma. The study met its primary endpoint of progression-free survival in patients who had prior treatments. This outcome suggests ELREXFIO's potential as an effective monotherapy for this patient group.
Market Sentiment Analysis
POSITIVE FACTORS
ELREXFIO met its primary endpoint in the study.
The drug showed improved progression-free survival.
Results were based on a significant patient population.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
PF-07817883
Phase 2 · SARS-CoV-2 Infection
Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatuximab) and lenalidomide. At the pre-specified interim analysis for efficacy, the study met its primary endpoint of progression-free survival (PFS) as assessed by blinded ind
Frequently Asked Questions
What is ELREXFIO used for?
ELREXFIO is used as a treatment for relapsed or refractory multiple myeloma.
What were the results of the Phase 3 study?
The study met its primary endpoint of progression-free survival.
Who were the participants in the study?
Participants were adults with RRMM who had prior treatments.
What is the significance of the primary endpoint?
Meeting the primary endpoint indicates the drug's effectiveness in improving survival.